Drug-drug InteractionsPINGNCT04710615
Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
A study testing Synapse platform in people with Drug-drug Interactions and Geriatric Disease, run by University Hospital, Bordeaux at 5 sites in France.
Trial summary
Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Drug-drug Interactions, Geriatric Disease
- What is being tested?
- Synapse platform
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 178 participants
- Where
- 5 sitesFrance
- Study dates
- 5 Oct 2021to 20 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Male or female age aged more than 65 years
- Hospitalization in geriatric department at Bordeaux University Hospital or Libourne Hospital
- Initial drug prescription with at least 2 active pharmaceutical ingredients
- Affiliation to French social security
- Written informed consent signed by participant and investigator
Who cannot join
- Adults protected by law
- Subject included in a clinical trial with an experimental treatment
- Subject during exclusion period relative to another trial
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
France5 sites
CHU de Bordeaux, Hôpital Pellegrin
Bordeaux, 33000
CHU de Bordeaux
Bordeaux, 33000
Centre Hospitalier de Libourne - Pôle Gériatrie
Libourne, 33500
CHU de Bordeaux, Hôpital Xavier Arnozan
Pessac, 33400
CHU de Bordeaux, Hôpital Xavier Arnozan
Pessac, 33600
About this study
Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.
Read the detailed description
The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.
The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.
More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:
- Indications, contraindications, dosage and adverse effects of drugs.
- STOPP criteria.
- START criteria.
- Associations at risk for drug-drug interactions.
Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.
This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.
Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.
- Conditions
- Drug-drug Interactions, Geriatric Disease
- Being tested
- Synapse platform
- Keywords
- Drugs, artificial, intelligence, medications, Elderly
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Synapse platformDevice
The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.
The Synapse platform offers a panel of functions to help the doctor to prescribe medication.
| Study group | Role | What they receive |
|---|---|---|
| Assistance device | Experimental | With prescription assistance device:
During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline). Receives: Device: Synapse platform |
| No device | No intervention | During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, … |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
Proportion of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
Measured: Month 6
Secondary outcomes (11)
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Proportion of patients with increase in START criteria number between initial prescription and exist prescription.
Measured: Day 1
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Proportion of patients with increase in START criteria number between initial prescription and exist prescription.
Measured: Month 6
Number of STOPP criteria
Difference in the number of STOPP criteria between initial and discharge prescription
Measured: Day 1
Number of STOPP criteria
Difference in the number of STOPP criteria between initial and discharge prescription
Measured: Month 6
Number of START criteria
Difference in the number of START criteria between initial and discharge prescription.
Measured: Day 1
Number of START criteria
Difference in the number of START criteria between initial and discharge prescription.
Measured: Month 6
number of patients with decrease in contraindicated drug-drug interaction
Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription
Measured: Day 1
number of patients with decrease in contraindicated drug-drug interaction
Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription
Measured: Month 6
Number of patients with decrease if active pharmaceutical ingredients
Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription
Measured: Day 1
Number of patients with decrease if active pharmaceutical ingredients
Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription
Measured: Month 6
Number of connections per week on Synapse platform by geriatricians
Number of connections per week on Synapse platform by geriatricians
Measured: Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2021
- Study start5 Oct 2021
- Primary completion20 Apr 2024
- Study completion20 Apr 2024
Why it stopped: Target number of subject not reached, termination due to recruitement contraints
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Drug-drug InteractionsStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 178 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Pierre-Olivier GIRODET, MD, PhD, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04710615
- Sponsor's protocol ID
- CHUBX 2019/33
- Acronym
- PING
- Status last verified
- Jan 2024
- First submitted
- 8 Jan 2021
- Last updated
- 24 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
- ClinicalTrials.gov ID
- NCT04710615
- Acronym / sponsor ID
- PING / CHUBX 2019/33
- Conditions
- Drug-drug Interactions, Geriatric Disease
- Keywords
- Drugs, artificial, intelligence, medications, Elderly
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Target number of subject not reached, termination due to recruitement contraints
- Enrolment
- 178 participants (actual)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 5 Oct 2021 (actual)
- Primary completion
- 20 Apr 2024 (actual)
- Study completion
- 20 Apr 2024 (actual)
- First posted
- 14 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.
Detailed description
The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.
The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.
More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:
- Indications, contraindications, dosage and adverse effects of drugs.
- STOPP criteria.
- START criteria.
- Associations at risk for drug-drug interactions.
Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.
This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.
Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Assistance device | Experimental | Device: Synapse platformWith prescription assistance device: During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline). |
| No device | No intervention | –During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, … |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (5 listed)
Key exclusion criteria (3 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Synapse platformThe Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions. The Synapse platform offers a panel of functions to help the doctor to prescribe medication. | Device | Assistance device |
Primary outcome
Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
Time frame: Month 6
Proportion of patients with decrease in STOPP criteria number between initial prescription and exist prescription.
11 secondary outcomes
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Time frame: Day 1
Number of patients with increase in START criteria number between initial prescription and exist prescription.
Time frame: Month 6
Number of STOPP criteria
Time frame: Day 1
Number of STOPP criteria
Time frame: Month 6
Number of START criteria
Time frame: Day 1
Number of START criteria
Time frame: Month 6
number of patients with decrease in contraindicated drug-drug interaction
Time frame: Day 1
number of patients with decrease in contraindicated drug-drug interaction
Time frame: Month 6
Number of patients with decrease if active pharmaceutical ingredients
Time frame: Day 1
Number of patients with decrease if active pharmaceutical ingredients
Time frame: Month 6
Number of connections per week on Synapse platform by geriatricians
Time frame: Month 6
Results and safety
The study was stopped early (reason given: Target number of subject not reached, termination due to recruitement contraints). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Drug-drug Interactions
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingPhase 1
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Healthy Volunteer, Pharmacokinetics
RecruitingPhase 1
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
Healthy
Not yet recruitingPhase 1
LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study
PK Drug-drug Interaction Study
Active, not recruitingPhase 1
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pierre-Olivier GIRODET, MD, PhD principal investigator
University Hospital, Bordeaux
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Synapse platform in people with Drug-drug Interactions and Geriatric Disease, run by University Hospital, Bordeaux at 5 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Target number of subject not reached, termination due to recruitement contraints). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription. (time frame: Month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.